Literature DB >> 15103320

Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.

E Rollman1, J Hinkula, J Arteaga, B Zuber, A Kjerrström, M Liu, Britta Wahren, Karl Ljungberg.   

Abstract

A highly desirable feature for an human immunodeficiency virus type 1 (HIV-1) vaccine is the ability to induce broadly reactive anti-envelope antibodies that can neutralize primary HIV-1 isolates. Two immunizations with an HIV-1 envelope-encoding plasmid together with recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) resulted in high antibody titers in mice. The antibody induction was further enhanced after immunization with genes encoding HIV-1 envelopes originating from subtypes A, B and C. The sera from these animals were able to neutralize A, B and C viral isolates, whereas the sera from animals immunized solely with subtype B DNA neutralized only subtype B virus. The combined DNA vaccine gave serum antibodies with broad recognition of HIV-1 envelope epitopes as determined by peptide mapping. Cell-mediated immunity was not compromised by the increased humoral immunity. This demonstrates the ability of multiple envelope genes to induce the desired antibody response against several subtypes. Moreover, it documents the ability of rGM-CSF to enhance the potency of such a vaccine when given simultaneously. The strategy may be useful for making an HIV vaccine more potent and broadly effective against strains of different clades.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15103320     DOI: 10.1038/sj.gt.3302275

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

Review 2.  Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Authors:  Flavia Ferrantelli; Stefano Buttò; Aurelio Cafaro; Britta Wahren; Barbara Ensoli
Journal:  Springer Semin Immunopathol       Date:  2006-09-16

3.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

4.  Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.

Authors:  Jorge A Tavel; Julie E Martin; Grace G Kelly; Mary E Enama; Jean M Shen; Phillip L Gomez; Charla A Andrews; Richard A Koup; Robert T Bailer; Judy A Stein; Mario Roederer; Gary J Nabel; Barney S Graham
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-15       Impact factor: 3.731

Review 5.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

6.  Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Authors:  Eric Sandström; Charlotta Nilsson; Bo Hejdeman; Andreas Bråve; Göran Bratt; Merlin Robb; Josephine Cox; Thomas Vancott; Mary Marovich; Richard Stout; Said Aboud; Muhammad Bakari; Kisali Pallangyo; Karl Ljungberg; Bernard Moss; Patricia Earl; Nelson Michael; Deborah Birx; Fred Mhalu; Britta Wahren; Gunnel Biberfeld
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

Review 7.  Polyvalent AIDS vaccines.

Authors:  Shan Lu; Jill M Grimes Serrano; Shixia Wang
Journal:  Curr HIV Res       Date:  2010-12       Impact factor: 1.581

Review 8.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

9.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

10.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.